KODAK OFFERING CONTRACT BIOTECH R&D AND PRODUCTION SERVICES
Executive Summary
KODAK OFFERING CONTRACT BIOTECH R&D AND PRODUCTION SERVICES, the company's Bio-Products division announced in an April 29 press release. "The 'Bio-Manufacturing Program,' as the service has been named, is designed to assist organizations that may need to complement their own resources with the capabilities of the Bio-Products division in process development, scale-up and production," Kodak stated. Kodak explained that potential clients might include companies involved in biotech research, offshore companies seeking U.S. production or companies that have only a short-term need for capacity. The company indicated that the new program would have no effect on Kodak's existing agreements with other companies. The firm said its 66,000 sq. ft. pilot plant, intended for scale-up and low volume production, is currently in the final stages of construction. "We have fermentation equipment in a wide range of sizes and we have technical staff skilled in all areas of biochemical development and manufacturing," Kodak commented. "We have the resources to assist and counsel in all aspects of biochemcial manufacturing, from the process development stage to marketing the end product -- and everything in between."
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth